Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
about
Spasticity in multiple sclerosis and role of glatiramer acetate treatment.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyDelta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.Botulinum toxin for symptomatic therapy in multiple sclerosis.Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant.Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.Advances in the management of MS symptoms: recently proposed clinical management algorithms.Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions.Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force.Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.Prescribed psychiatric medication among multiple sclerosis patients before and after disability pension: a register study with matched controls.The high cost of spasticity in multiple sclerosis to individuals and society.A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.Direct, long-term intrathecal application of therapeutics to the rodent CNS.
P2860
Q36109866-D816B995-A015-40FD-AF2F-ABEF15D33263Q36171531-B40EE961-1A0E-4FB7-A3E1-EF3ABE50EBE1Q38199658-F3D0DE83-E824-4833-8761-0B3141A55FD0Q38222194-27C16B01-AF94-468B-9908-8CA6E0EB9367Q38240853-D7A31098-1D0C-4505-9D7F-F0EB0F21396DQ38647620-955B2905-EBF1-4221-90A8-1FECB467DC73Q38649275-2EB2753C-A67B-4AE7-B338-6856AFB2868AQ38727855-93DBD50C-BE6E-4738-BDCE-E0DDBB4E1000Q38992567-E355CAEE-7F7C-4CAB-A453-9DAD4D0768A1Q39178828-E4DD9D41-96A6-4F8E-B4EF-872F40C4E33DQ39774100-2210269A-983B-4470-ACCE-04B2A47E16E7Q41523590-80B44717-8143-43B1-B6EE-3C24438FD534Q47859669-487005AE-D4C8-4001-956F-A6C0859096C4Q48395041-38343D21-292E-47BD-B868-2DE0EBFB0077
P2860
Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Advances in the management of ...... lerosis spasticity guidelines.
@en
type
label
Advances in the management of ...... lerosis spasticity guidelines.
@en
prefLabel
Advances in the management of ...... lerosis spasticity guidelines.
@en
P1476
Advances in the management of ...... lerosis spasticity guidelines.
@en
P2093
Celia Oreja-Guevara
P356
10.1586/14737175.2013.865880
P433
P577
2013-12-01T00:00:00Z